Amyloid β and Alzheimer disease therapeutics: The devil may be in the details

Journal of Clinical Investigation

Volumn 112, Issue 3, 2003, Pages 321-323

  Cirrito, John R ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; AUTOANTIGEN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; INFLAMMATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW; AGING; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; IMMUNOLOGY; METABOLISM; NOTE; T LYMPHOCYTE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOANTIGENS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INFLAMMATION; MICE; T-LYMPHOCYTES;

EID: 85047693300     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19420     Document Type: Review

References (13)

1. Schenk, D., et al. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.
2. DeMattos, R.B., et al. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 98:8850-8855.
3. Bard, F., et al. 2000. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919.
4. Monsonego, A., et al. 2003. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112:415-422. doi:10.1172/JCI200318104.
5. Eriksen, J.L., et al. 2003. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. doi:10.1172/JCI200318162.
6. Morris, J.C., and Price, A.L. 2001. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 17:101-118.
7. Morgan, D., et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:982-985.
8. Janus, C., et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:979-982.
9. Dodart, J.C., et al. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
10. Kotilinek, L.A., et al. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:6331-6335.
11. Nicoll, J.A., et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9:448-452.
12. Town, T., et al. 2001. Characterization of murine immunoglobulin G antibodies against human amyloid-β1-42. Neurosci. Lett. 307:101-104.
13. Hock, C., et al. 2002. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8:1270-1275.